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ABSTRACT
Objective Most patients with atrial fibrillation (AF) 
report symptoms, while one- third are asymptomatic. We 
hypothesised that sensory processing, in particular pain, 
differs in patients with symptomatic and asymptomatic AF.
Methods Thirty individuals with permanent AF (15 
symptomatic and 15 asymptomatic) completed the 
Atrial Fibrillation 6 (AF6) and short form 36 Health 
Survey questionnaires and underwent quantitative pain 
sensitisation testing using pressure algometry at the 
sternum (referred pain area) and the tibialis anterior 
muscle (generalised pain area). The primary objective 
was to assess differences in pressure pain thresholds 
(PPT), temporal summation of pain (TSP) and conditioned 
pain modulation (CPM) in the two groups. The secondary 
objective was to determine association of demographic 
and clinical parameters to measures of pain sensitisation.
Results The symptomatic group had lower PPTs at both 
tibialis (p=0.004) and sternum (p=0.01), and impaired 
CPM (p=0.025) and facilitated TSP (p=0.008) at the tibialis 
but not sternum, compared with the asymptomatic group. 
The AF6 sum score was negatively correlated to PPT on 
both tibialis (r=−0.50, p=0.005) and sternum (r=−0.42, 
p=0.02) and positively correlated to TSP on both tibialis 
(r=0.57, p=0.001) and sternum (r=0.45, p=0.01), but not 
to CPM. The physical component summary score was 
positively correlated to the PPT on both tibialis (r=0.52, 
p=0.003) and sternum (r=0.40, p=0.03) and negatively to 
TSP on the tibialis (r=−0.53, p=0.003) but not sternum.
Conclusions Patients with symptomatic AF exhibit lower 
pain tolerance than patients with asymptomatic AF, as 
well as impaired pain inhibitory control and facilitated 
summation of pain, indicating that pain sensitisation may 




Approximately one- third of individuals with 
atrial fibrillation (AF) report no symptoms, 
but up to 25% report severe symptoms such 
as palpitations, dyspnoea, chest pain and 
syncope.1 2 In studies of patients with perma-
nent AF, 9%–15% reported chest pain.3 4 
About one- third of patients with symptomatic 
AF also suffer from psychological distress.5 6 
It remains unclear why some individuals with 
AF are asymptomatic, whereas others are 
severely symptomatic. Patients with chronic 
pain conditions such as osteoarthritis, chronic 
pancreatitis and irritable bowel syndrome 
show a high degree of pain sensitisation, that 
is, facilitated pain responses to repeat painful 
stimulation and impaired pain inhibitory 
control compared with controls.7–9 It is not 
known whether patients with symptomatic 
AF exhibit a high degree of pain sensitisation 
in the absence of chest pain as a symptom. 
We hypothesised that pain sensitisation is an 
important factor driving symptom perception 
in AF. The primary objective of this study was 
to assess differences in pain sensitisation in 
patients with symptomatic and asymptomatic 
AF. The secondary objective was to analyse 
associations of demographic (age, sex and 
body mass index (BMI)) and clinical parame-
ters (AF duration, Atrial Fibrillation 6 (AF6) 
sum score and physical and mental compo-
nent summary scores of the short form 36 
Key questions
What is already known about this subject?
 ► It is unclear why some individuals with atrial fibril-
lation (AF) experience symptoms whereas others 
are asymptomatic, and little is known of the physi-
ological mechanisms underlying AF symptomology. 
Previous studies have found that symptomatic AF is 
more frequent in women, at younger ages, and in 
patients with non- permanent AF. It is possible that 
patients with symptomatic AF differ in pain process-
ing from those not perceiving symptoms.
What does this study add?
 ► Patients with symptomatic AF show significant signs 
of pain sensitisation compared with patients with no 
perceived symptoms of AF.
How might this impact on clinical practice?
 ► Our findings suggest there is potential for investi-
gation of therapies to target pain sensitisation in 
patients with symptomatic AF.
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Study participants were recruited from a database 
consisting of all individuals aged 20 years or older with an 
initial or recurrent AF diagnosis between 1 January 2015 
and 31 December 2018 in Örebro County, Sweden. The 
database comprised patients derived from the Medrave 4 
Registry for primary care, the Auricula Registry (national 
quality registry for anticoagulation treatment) and 
the National Patient Registry for inpatient and special-
ised outpatient care. Eligibility criteria for the current 
study were ≤75 years old, permanent AF (persistent AF 
for which no further attempts to restore sinus rhythm 
will be undertaken10) and a previously completed AF6 
questionnaire11 in spring of 2021. Reasons for exclusion 
were pregnancy, diabetes mellitus, previous AF ablation, 
psychiatric condition or cognitive impairment, drug or 
alcohol abuse, previous or concomitant neurological 
musculoskeletal disorder or continuous analgesic medi-
cation. Candidate participants received written study 
information and were offered an outpatient visit to a 
physician (AB) at the Department of Cardiology, Örebro 
University Hospital. Patients were asked not to take anal-
gesic medication within the 24 hours preceding the visit. 
After obtaining written informed consent, patients were 
asked to repeat the AF6 and SF-3612 questionnaires, rate 
their chest pain symptoms on the Visual Analogue Scale 
(VAS) and draw the area of pain on a body chart. Comor-
bidities, medications, duration of AF and ranking on the 
modified European Heart Rhythm Association (EHRA) 
symptom scale13 were documented, and a routine clinical 
examination was performed including a 12- lead ECG. All 
data were obtained during the visit and no follow- up visits 
were conducted. Subjects were divided into two groups 
based on their earlier AF6 sum scores: 15 asymptomatic 
patients with an AF6 sum score of 0, and 15 symptomatic 
patients with an AF6 sum score of ≥30. The cut- off of 30 
was based on a study showing patients scheduled for AF 
ablation, who are generally highly symptomatic, to have 
a median score of 30 points.14 Sample size flat rules of 
thumb was used as this was a proof- of- concept study.15 
The study was conducted in accordance with the Declara-
tion of Helsinki.
Symptom assessment and health-related quality of life
The patient- reported AF6 questionnaire has a recall 
period of 7 days and includes breathing difficulties at 
rest, breathing difficulties on exertion, limitations in 
day- to- day life, feeling of discomfort, tiredness and worry 
and/or anxiety due to AF. A score of 0 (no symptoms) to 
10 (severe symptoms) is reported for each of the six items 
and scores are added to obtain a cumulative sum score 
ranging from 0 to 60, with higher values reflecting more 
severe symptoms.11 16
The physician- assessed modified EHRA scale was used 
to assess symptom severity relating specifically to the time 
when patients feel symptoms of AF. Patients reporting no 
AF symptoms are categorised as class I. Class IIa experi-
enced mild, class IIb moderate, class III severe and class 
IV, disabling symptoms.13
The patient- reported SF-36 has a recall period of 
4 weeks and consists of 36 items assessing eight domains 
on a scale ranging from 0 to 100, with higher values 
indicating better health- related quality of life. The eight 
domains generate a physical component summary score 
and a mental component summary score, which were 
used to assess health- related quality of life.12
Quantitative sensory testing
Quantitative sensory tests were conducted by a blinded 
investigator (AJ) in the following order: pressure pain 
threshold (PPT), temporal summation of pain (TSP) 
and conditioned pain modulation (CPM). PPTs and TSP 
were performed at the tibialis anterior muscle 5 cm distal 
to the tibial tuberosity, and at the sternum between the 
third and fifth intercostal spaces, with 1 min intervals 
between repeats and sites.17 The sites were chosen to 
reflect localised (sternum, referred pain area) and gener-
alised (tibialis anterior muscle) manifestations of sensiti-
sation. Patients were free to stop the test at any time.
PPT
The PPT was defined as the minimum pressure required 
for the sensation of pressure to change to pain. The 1 cm2 
probe of the handheld pressure algometer (Somedic AB, 
Sweden) was placed perpendicular to the skin, and pres-
sure was increased at a rate of approximately 30 kPa/s. 
Participants were instructed to press the stop button on 
the algometer when they first experienced the sensation 
of pain. The mean of three measurements at each site was 
used for analysis.
TSP
A pin- prick device (0.25 mm2 tip) with a weighted load 
(Aalborg University, Denmark) was used to induce 
TSP.18 19 A force of 60 g was applied to both sites, and 
patients were asked to rate the pain intensity on a VAS 
(0 to 10). Ten consecutive stimuli were applied with a 1 s 
interval between stimuli and the subjects were asked to 
rate the pain intensity of the final stimulation on the VAS. 
Temporal summation of pain was defined as the differ-
ence in pain intensity between the first and the final stim-
ulation. Higher TSP scores indicated facilitated temporal 
summation.
CPM
The right hand was immersed up to the wrist in circu-
lating water at 2°C–4 °C for up to 2 min (cold pressor test). 
The PPT from both sites were assessed before (uncon-
ditioned) and after (conditioned) the 2 min immersion 
and reassessed 10 minutes after the hand was withdrawn 
from the water. The CPM was calculated as the absolute 
difference in PPT during the immersion compared with 
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the pre- immersion PPT. A negative value indicates ineffi-
cient CPM and a positive value indicates efficient CPM.
Statistical analysis
Data were tested for normality using the Shapiro- Wilk’s 
test. Independent sample t- tests were performed to 
analyse differences between groups in age, BMI, AF dura-
tion and physical/mental component summary scores, 
and dependent sample t- tests to quantify difference in 
initial and repeat AF6 sum scores.
The χ2 test was employed to test for differences in 
sex, comorbidities, rate control agents (beta- blockers, 
verapamil, diltiazem and digoxin individually or 
combined), and completion of the full 2 min immer-
sion cold pressor test between the two groups. A mixed 
model analysis of variance (ANOVA) was used to assess 
the primary objective of the study, with within- factor 
time (baseline, 2 min and 10 min), and between groups. 
One- way ANOVA was used to characterise differences 
in CPM and TSP. To adjust for age, sex and BMI, these 
variables were included as covariates for CPM and TSP. 
Sidak- corrected post hoc tests were employed where 
appropriate, if main or interaction factors were signifi-
cant. Secondary objectives were tested using correlational 
analyses, Pearson’s product- moment or Spearman’s rank 
correlation where appropriate for demographic and 
clinical parameters, and pain sensitisation as reflected 
by PPT, CPM and TSP. A p<0.05 was considered signifi-
cant. Data were reported as mean±SEM unless otherwise 
stated. Statistical analyses were performed using IBM 
SPSS Statistics V.27.
Patient and public involvement
Patients and public were not invited to comment on the 
study design and were not consulted to develop outcomes 
relevant to patients or to interpret the results. Patients 
were not invited to contribute to the writing or editing of 
this document for readability or accuracy. Before publi-
cation, the results of this study were not disseminated to 
patients or the public.
RESULTS
Study population—clinical characteristics
Thirty patients were enrolled in the study between 
November 2020 and January 2021 (mean age 69±6 years, 
60% men, duration of AF 7±4 years) (table 1).
The groups were well matched, except for a significantly 
higher BMI in the symptomatic group (t (17.8)=−3.73, 
p=0.002). The resting heart rate was adequately rate 
controlled in all patients with no significant differences 
between the groups and no significant differences in 
treatment with rate control agents.
Symptoms of AF and health-related quality of life
Patients in the symptomatic group had significantly lower 
AF6 sum scores at inclusion in the study (30±11) than 
recorded in spring of 2020 (38±8, t=2.97, p=0.01), while 
all asymptomatic patients had an AF6 sum score of 0 both 
times. The item consistently scoring as most severe was 
breathing difficulties on exertion (table 2).
Patients with symptomatic AF were considered to be 
in EHRA class IIa–III, whereas all asymptomatic patients 
were considered to be in EHRA class I. Symptomatic 
patients reported significantly lower physical and mental 
component summary scores compared with asymptomatic 
Table 1 Characteristics of patients with symptomatic 





Male—n (%) 8 (53) 10 (67)
Age—years, mean (SD) 69 (7) 69 (4)
Body mass index—kg/m2 32 (7) 25 (3)
Concomitant disease—n (%)
  Hypertension 10 (67) 10 (67)
  Heart failure 0 0
  Coronary artery disease 1 (7) 0
  Peripheral artery disease 0 0
  History of stroke or TIA 0 2 (13)
  Chronic kidney disease 0 0
  Obstructive sleep apnoea 4 (27) 4 (27)
AF history and symptoms
  Duration of AF—years, 
mean (SD)
7 (4) 7 (4)
  Heart rate at rest—beats/
min, mean (SD)
80 (13) 71 (12)
  CHA2DS2- VASc scores, 
mean (SD)
1.9 (1.3) 1.7 (0.9)
  AF6 sum score inclusion, 
mean (SD)
30 (11) 0
  EHRA symptom scale class 
n (%)
   I 0 (0) 15 (100)
   IIa 8 (53) 0
   IIb 5 (33) 0
   III 2 (13) 0
   IV 0 0
Medications—n (%)
  Oral anticoagulation 13 (87) 14 (93)
  Beta- blockers 14 (93) 10 (67)
  Verapamil or diltiazem 1 (7) 0
  Digoxin 1 (7) 0
  ARB or ACE inhibitor 10 (67) 8 (53)
AF6, Atrial Fibrillation 6; AF, atrial fibrillation; ARB, angiotensin 
receptor blocker; CHA2DS2- VASc, congestive heart failure, 
hypertension, age ≥75 years (doubled), diabetes, prior stroke or 
transient ischaemic attack (doubled), vascular disease, age 65–74, 
female; EHRA, European Heart Rhythm Association; TIA, transient 
ischaemic attack.
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patients (t(19.19)=8, p<0.001 and t(21.696)=5.27, respec-
tively, p<0.001).
Four patients (13%) reported chest pain at some point 
during the prior 7 days, all of whom were in the symptom-
atic group (VAS 4, 6, 8 and 8). A body chart with super-
imposed chest pain distribution is shown in figure 1. 
Three of the patients who reported chest pain had previ-
ously undergone coronary angiography or radionuclide 
myocardial perfusion imaging with normal results. The 
fourth patient had undergone percutaneous coronary 
intervention due to myocardial infarction 5 years before 
diagnosis of AF.
Quantitative sensory testing
An overview of quantitative sensory testing values is avail-
able as online supplemental material.
Pressure pain threshold
The mixed model ANOVA did not reveal significant inter-
action between time and group (F1.34,37.53 =0.52, p=0.53, 
η2=0.02) but a significant main effect of time (F1.34,37.53 
=6.11, p=0.01, η2=0.18) on sternum PPTs was found. Post 
hoc between- group analysis showed significantly lower 
PPTs on the sternum for symptomatic patients (F1,28 =7.49, 
p=0.01, η2=0.21), and PPTs were significantly increased 2 
min (p=0.02) and 10 min (p=0.04) after hand immersion 
overall (figure 2). Similarly, no significant interaction was 
found for time and group for PPTs on the tibialis anterior 
muscle (F1.57,44.05 =2.13, p=0.14, η
2=0.071) or main effect of 
time (F1.57,44.05=2.11, p=0.14, η
2=0.07). Patients with symp-
tomatic AF reported lower PPTs over the tibialis anterior 
muscle than did the asymptomatic group (p=0.004).
Temporal summation of pain
When adjusting for age, sex and BMI, we found higher 
TSP in data of the tibialis anterior muscle in the symp-
tomatic group when compared with the asymptomatic 
group (p=0.008). There was no significant difference 
between asymptomatic and symptomatic AF patients in 
sternum TSP (p=0.13).
Conditioned pain modulation
All asymptomatic patients kept their hand immersed 
in the cold water for the full 2 min, while those in the 
Table 2 Atrial fibrillation symptoms in symptomatic 








Breathing difficulties at rest 13/15 3.2 (2.6)
Breathing difficulties on 
exertion
15/15 7 (2.6)
Limitations in day- to- day 
life
15/15 5.3 (2.8)
Feeling of discomfort 12/15 4.2 (3.4)
Tiredness 15/15 5.9 (3)
Worry and/or anxiety 13/15 4.4 (3)
AF6, Atrial Fibrillation 6.
Figure 1 Superimposed body chart (n=4) of chest pain 
distribution in patients with permanent atrial fibrillation.
Figure 2 Pressure pain thresholds (PPTs) before and after 
the cold pressor test. PPTs over the tibialis anterior muscle 
(A) and the sternum (B) before and immediately after cold 
pressor test in patients with symptomatic and asymptomatic 
permanent atrial fibrillation (AF). Values are mean and SEM 
of three measurements. #, sternum and tibial PPTs differed 
significantly in asymptomatic and patients with symptomatic 
AF, p<0.05. *, sternum PPTs were significantly increased 
immediately after and 10 min after cold pressor test 
compared with baseline, p<0.05.
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symptomatic group withdrew their hand significantly 
sooner (χ2=6, p=0.01). Sternum CPM, assessed by one- 
way ANOVA adjusted for age, sex and BMI, was not signif-
icantly different between groups (p=0.16). Conversely, 
CPM over the tibialis anterior muscle, adjusted for age, 
sex and BMI, was significantly higher in the asymptomatic 
group compared with the symptomatic group (p=0.025). 
No patient showed angina pectoris, bradycardia, or 
syncope during the cold pressor test.
Correlation analyses
We found a significant negative correlation between the 
AF6 sum score and PPTs of both the tibialis anterior muscle 
(r=−0.50, p=0.005) and the sternum (r=−0.42, p=0.02). 
There was a significant positive correlation of the AF6 
sum score with TSP of both the tibialis anterior muscle 
(r=0.57, p=0.001) and the sternum (r=0.45, p=0.01). 
There were significant correlations between the physical 
component summary scores and the PPTs of both the tibi-
alis anterior muscle (r=0.52, p=0.003) and the sternum 
(r=0.40, p=0.03) and significant negative correlation with 
TSP of the tibialis anterior muscle (r=0.53, p=0.003) but 
not the sternum. We observed significant positive corre-
lation between the mental summary scores and the CPM 
of the tibialis anterior muscle (r=0.40, p=0.03) but not of 
the sternum or other measures of pain sensitisation. Male 
sex was significantly positively correlated to PPT of the 
tibialis anterior muscle (r=0.42, p=0.02) and CPM of the 
sternum (r=0.49, p=0.006).
DISCUSSION
The study showed significant quantitative signs of local 
and general pain sensitisation in patients with permanent 
symptomatic AF as compared with patients with asymp-
tomatic AF, and significant correlation between quan-
titative pain sensitisation parameters and AF symptom 
severity scores.
Symptoms of AF
Little is known about the pathophysiological mechanisms 
underlying AF symptomatology.20 Several studies have 
evaluated the relationship between patient characteris-
tics and the presence of AF symptoms, and have found 
that asymptomatic AF is more frequent in men than in 
women, in older age and in patients with permanent 
AF.20–22 Furthermore, episodes of asymptomatic AF are 
common even in highly symptomatic patients, and AF 
interventions such as AF ablation increase the propor-
tion of asymptomatic to symptomatic AF episodes.23 
Symptoms of AF are highly variable in individual patients 
at different points in time,20 which is confirmed in the 
present study by the significant change in AF6 sum scores 
for patients with symptomatic AF from roughly 6 months 
before the study to inclusion. We chose 30 points as the 
AF6 sum score cut- off for symptomatic patients, and this 
corresponded well with a median score of 28 at inclusion.
This study included patients with permanent AF to 
avoid taking into account if patients had sinus rhythm or 
AF during quantitative sensory testing in this first proof- 
of- concept study, even though patients with permanent 
AF are the least symptomatic compared with patients 
with paroxysmal and persistent AF. It is possible that 
even greater differences in pain sensitisation would have 
been observed in a study including patients with non- 
permanent AF. An AF duration of 7 years is long, and 
patients tend to adapt to symptoms.20 We cannot rule out 
that patients in the asymptomatic group initially expe-
rienced symptoms. However, all asymptomatic patients 
reported an AF6 sum score of 0 both 6 months prior to 
the study and at inclusion.
The groups were well matched, although the symp-
tomatic group had a higher BMI. Obesity is a known 
risk factor for AF and obese patients have more diastolic 
dysfunction, sympathicotonia and increased fatty and 
inflammatory infiltration of the atria compared with 
normal- weight patients with AF.24 In addition, due to low- 
grade inflammation, obese patients show signs of gener-
alised pain sensitisation,25 which may to some degree 
contribute to pain processing in the patients with symp-
tomatic AF with higher BMI. Considerable weight reduc-
tion has been shown to reduce both AF recurrences and 
symptoms in patients with non- permanent AF.26
Quantitative sensory testing
The present study showed lower pressure pain thresholds 
over the referred pain area to the heart (sternum) and a 
distant area (tibialis anterior muscle) indicating both local 
and widespread pain sensitisation in patients with sympto-
matic AF.
The facilitated TSP in humans most likely reflects 
increased gain of the dorsal horn neurons, as shown in 
other animals.27 The CPM most likely reflects the balance 
between the descending pain inhibitory and facilia-
tory pathways.19 28 29 Both TSP and CPM reflect central 
changes in pain processing as involved in many chronic 
pain conditions.28 The mechanisms of pain sensitisation 
in humans are not fully understood, but for patients with 
symptomatic AF there may be links to other visceral disor-
ders where pain is facilitated.9 30
The AF6 sum score demonstrated strong correlations 
with both TSP (positive) and PPT (negative), but no 
significant correlations to CPM. This could indicate an 
association between AF symptom severity and pain ampli-
fication but warrants further study.
The study raises important questions: (1) does AF affect 
pain mechanisms and increase pain sensitivity per se, or 
is pain sensitivity an individual trait; (2) are some patients 
with AF a priori more pain susceptible than others; and 
(3) does pain sensitisation persist during periods without 
AF in patients with non- permanent AF?
Clinical relevance and limitations
In addition to existing treatment options for symptom relief 
such as rate control and lifestyle modifications, this study 
suggests evaluation therapies targeting pain and pain sensiti-
sation in patients with symptomatic AF. Our methods should 
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be replicated in larger cohorts and in patients with non- 
permanent AF.
This study has several limitations. It included a small 
sample size, but differences were identified between symp-
tomatic and asymptomatic groups. Second, and possibly 
more important, we lacked a control group without AF 
and the study should be considered hypothesis generating. 
Finally, we excluded patients with neurological and musculo-
skeletal disorders and diabetes to minimise the risk that some 
patients could be sensitised due to other conditions, but we 
cannot exclude the possibility that patients had unstated 
previous or intermittent pain conditions.
CONCLUSIONS
Patients with symptomatic AF show substantial signs of 
quantitative pain sensitisation compared with patients with 
asymptomatic AF, and pain sensitisation increases with an 
AF symptom severity score. This suggests the need for new 
management strategies to modulate symptoms of AF.
Twitter Ole Frobert @FrobertOle
Contributors All authors made substantial contributions to the conception and 
design of the work. AJ and AB acquired the data. All authors took part in the 
analysis and interpretation of data, drafting of the manuscript and approved the 
final version. All authors agree to be accountable for all aspects of the work.
Funding The authors have not declared a specific grant for this research from 
any funding agency in the public, commercial or not- for- profit sectors. Center for 
Neuroplasticity and Pain (CNAP) is supported by the Danish National Research 
Foundation (DNRF121).
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval Swedish Ethical Review Authority 2020-01619.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available upon reasonable request.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iD
Anna Björkenheim http:// orcid. org/ 0000- 0002- 4288- 3310
REFERENCES
 1 Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: 
prevalence, prognosis, quality of life, and management. J Interv Card 
Electrophysiol 2000;4:369–82.
 2 Patel N, Chung EH, Mounsey JP, et al. Effectiveness of atrial 
fibrillation monitor characteristics to predict severity of symptoms of 
atrial fibrillation. Am J Cardiol 2014;113:1674–8.
 3 Lip GYH, Laroche C, Ioachim PM, et al. Prognosis and treatment of 
atrial fibrillation patients by European cardiologists: one year follow- 
up of the EURObservational research Programme- Atrial fibrillation 
General registry pilot phase (EORP- AF pilot registry). Eur Heart J 
2014;35:3365–76.
 4 Nabauer M, Gerth A, Limbourg T, et al. The registry of the German 
competence network on atrial fibrillation: patient characteristics and 
initial management. Europace 2009;11:423–34.
 5 Thrall G, Lip GYH, Carroll D, et al. Depression, anxiety, and quality of 
life in patients with atrial fibrillation. Chest 2007;132:1259–64.
 6 Lane DA, Langman CM, Lip GYH, et al. Illness perceptions, affective 
response, and health- related quality of life in patients with atrial 
fibrillation. J Psychosom Res 2009;66:203–10.
 7 Arendt- Nielsen L, Nie H, Laursen MB, et al. Sensitization in patients 
with painful knee osteoarthritis. Pain 2010;149:573–81.
 8 Olesen SS, Brock C, Krarup AL, et al. Descending inhibitory pain 
modulation is impaired in patients with chronic pancreatitis. Clin 
Gastroenterol Hepatol 2010;8:724–30.
 9 Wilder- Smith CH, Robert- Yap J. Abnormal endogenous pain 
modulation and somatic and visceral hypersensitivity in female 
patients with irritable bowel syndrome. World J Gastroenterol 
2007;13:3699–704.
 10 Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for 
the diagnosis and management of atrial fibrillation developed in 
collaboration with the European association for Cardio- Thoracic 
surgery (EACTS). Eur Heart J 2021;42:373–498.
 11 Härdén M, Nyström B, Kulich K, et al. Validity and reliability of a 
new, short symptom rating scale in patients with persistent atrial 
fibrillation. Health Qual Life Outcomes 2009;7:65.
 12 McHorney CA, Ware JE, Lu JF, et al. The mos 36- item short- 
form health survey (SF-36): III. tests of data quality, scaling 
assumptions, and reliability across diverse patient groups. Med Care 
1994;32:40–66.
 13 Wynn GJ, Todd DM, Webber M, et al. The European Heart Rhythm 
Association symptom classification for atrial fibrillation: validation 
and improvement through a simple modification. Europace 
2014;16:965–72.
 14 Björkenheim A, Brandes A, Magnuson A, et al. Assessment of 
Atrial Fibrillation- Specific Symptoms Before and 2 Years After 
Atrial Fibrillation Ablation: Do Patients and Physicians Differ in 
Their Perception of Symptom Relief? JACC Clin Electrophysiol 
2017;3:1168–76.
 15 Browne RH. On the use of a pilot sample for sample size 
determination. Stat Med 1995;14:1933–40.
 16 Härdén M, Nyström B, Bengtson A, et al. Responsiveness of AF6, 
a new, short, validated, atrial fibrillation- specific questionnaire--
symptomatic benefit of direct current cardioversion. J Interv Card 
Electrophysiol 2010;28:185–91.
 17 Bergmann N, Ballegaard S, Holmager P, et al. Pressure pain 
sensitivity: a new method of stress measurement in patients with 
ischemic heart disease. Scand J Clin Lab Invest 2013;73:373–9.
 18 Neogi T, Guermazi A, Roemer F, et al. Association of joint 
inflammation with pain sensitization in knee osteoarthritis: the 
multicenter osteoarthritis study. Arthritis Rheumatol 2016;68:654–61.
 19 Arendt- Nielsen L, Yarnitsky D. Experimental and clinical applications 
of quantitative sensory testing applied to skin, muscles and viscera. 
J Pain 2009;10:556–72.
 20 Rienstra M, Lubitz SA, Mahida S, et al. Symptoms and functional 
status of patients with atrial fibrillation: state of the art and future 
research opportunities. Circulation 2012;125:2933–43.
 21 Walfridsson U, Steen Hansen P, Charitakis E, et al. Gender and age 
differences in symptoms and health- related quality of life in patients 
with atrial fibrillation referred for catheter ablation. Pacing Clin 
Electrophysiol 2019;42:1431–9.
 22 Reynolds MR, Lavelle T, Essebag V, et al. Influence of age, sex, and 
atrial fibrillation recurrence on quality of life outcomes in a population 
of patients with new- onset atrial fibrillation: the fibrillation registry 
assessing costs, therapies, adverse events and lifestyle (FRACTAL) 
study. Am Heart J 2006;152:1097–103.
 23 Hindricks G, Piorkowski C, Tanner H, et al. Perception of atrial 
fibrillation before and after radiofrequency catheter ablation: 
relevance of asymptomatic arrhythmia recurrence. Circulation 
2005;112:307–13.
 24 Huxley RR, Misialek JR, Agarwal SK, et al. Physical activity, obesity, 
weight change, and risk of atrial fibrillation: the Atherosclerosis risk 
in Communities study. Circ Arrhythm Electrophysiol 2014;7:620–5.
 25 McKendall MJ, Haier RJ. Pain sensitivity and obesity. Psychiatry Res 
1983;8:119–25.
 26 Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and 
cardiometabolic risk factor management on symptom burden and 
severity in patients with atrial fibrillation: a randomized clinical trial. 
JAMA 2013;310:2050–60.
 27 Arendt- Nielsen L, Petersen- Felix S. Wind- up and neuroplasticity: 
is there a correlation to clinical pain? Eur J Anaesthesiol Suppl 
1995;10:1–7.
 28 Arendt- Nielsen L, Morlion B, Perrot S, et al. Assessment and 
manifestation of central sensitisation across different chronic pain 
conditions. Eur J Pain 2018;22:216–41.
 29 Yarnitsky D, Arendt- Nielsen L, Bouhassira D, et al. 
Recommendations on terminology and practice of psychophysical 
DNIC testing. Eur J Pain 2010;14:339.
 30 Frøbert O, Arendt- Nielsen L, Bak P, et al. Pain perception and brain 
evoked potentials in patients with angina despite normal coronary 
angiograms. Heart 1996;75:436–41.
copyright.









eart: first published as 10.1136/openhrt-2021-001699 on 17 June 2021. D
ow
nloaded from
 
